가이던스 및 전망 - Benzinga

Comments

Alnylam Pharmaceuticals Inc 주식 안내

ALNYNASDAQ

대중과의 거래

대중과의 거래

$314.40

5.921.92%

가까이에: Feb 13, 4:00 PM EST

$314.40

N/A

시간외: Feb 13, 6:35 PM EST

실적: Q4 2025 실적이 목 2월 12th에 개장 전 발표되었습니다.

컨퍼런스 콜: 가장 최근의 컨퍼런스 콜은 4일 전 8:30 오전에 시작되었습니다.

웹캐스트를 보려면 클릭하세요.

개요 뉴스 실적 옵션가이던스/지침분석가 평가 내부자 거래 매도 수량 정부 거래 주식 보고서

가이던스 및 전망

Alnylam Pharmaceuticals은 향후 EPS 및 수익에 대한 지침을 발표하여 투자자에게 회사가 향후 기간에 얼마나 많은 수익을 낼 것으로 예상하는지에 대한 통찰력을 제공합니다.

											Get Alert
02/12/2026	ALNY	Alnylam Pharmaceuticals	FY	2026	—	—	—	$5.30B	$5.80B	$5.51B	Get Alert
10/30/2025	ALNY	Alnylam Pharmaceuticals	FY	2025	—	—	—	$3.60B	$3.80B	$3.57B	Get Alert
07/31/2025	ALNY	Alnylam Pharmaceuticals	FY	2025	—	—	—	$3.30B	$3.55B	$3.01B	Get Alert
05/01/2025	ALNY	Alnylam Pharmaceuticals	FY	2025	—	—	—	$2.70B	$3.00B	$2.89B	Get Alert
02/13/2025	ALNY	Alnylam Pharmaceuticals	FY	2025	—	—	—	$2.70B	$3.00B	$2.68B	Get Alert
10/31/2024	ALNY	Alnylam Pharmaceuticals	FY	2024	—	—	—	$2.15B	$2.30B	$2.23B	Get Alert
08/01/2024	ALNY	Alnylam Pharmaceuticals	FY	2024	—	—	—	$2.15B	$2.30B	$1.88B	Get Alert
05/02/2024	ALNY	Alnylam Pharmaceuticals	FY	2024	—	—	—	$1.73B	$1.93B	$1.85B	Get Alert
02/15/2024	ALNY	Alnylam Pharmaceuticals	FY	2024	—	—	—	$1.73B	$1.93B	$1.78B	Get Alert
11/02/2023	ALNY	Alnylam Pharmaceuticals	FY	2023	—	—	—	$1.77B	$1.91B	$1.44B	Get Alert
08/03/2023	ALNY	Alnylam Pharmaceuticals	FY	2023	—	—	—	$1.30B	$1.46B	$1.44B	Get Alert
05/04/2023	ALNY	Alnylam Pharmaceuticals	FY	2023	—	—	—	$1.30B	$1.46B	$1.39B	Get Alert
02/23/2023	ALNY	Alnylam Pharmaceuticals	FY	2023	—	—	—	$1.30B	$1.46B	$1.48B	Get Alert
10/27/2022	ALNY	Alnylam Pharmaceuticals	FY	2022	—	—	—	$970.00M	$1.08B	$1.07B	Get Alert
07/28/2022	ALNY	Alnylam Pharmaceuticals	FY	2022	—	—	—	$870.00M	$930.00M	$1.09B	Get Alert
04/28/2022	ALNY	Alnylam Pharmaceuticals	FY	2022	—	—	—	$870.00M	$930.00M	$1.17B	Get Alert

FAQ

Q

Alnylam Pharmaceuticals (ALNY)에 대한 가장 최근의 가이던스는 무엇인가요?

A

최근 몇 달간 Alnylam Pharmaceuticals에 대한 구체적인 매출이나 실적 지침이 보고되지 않았습니다.

사람들이 또한 지켜본다

Avidity Biosciences Inc

BeOne Medicines Ltd

Exact Sciences Corp

Neurocrine Biosciences Inc

Ionis Pharmaceuticals Inc

Roivant Sciences Ltd

United Therapeutics Corp

© 2026 Benzinga | All Rights Reserved